omniture
logo
Search
CALI BIOSCIENCES 加立生科
Media Room

Latest News

rss

Cali Biosciences Announces Publication of Successful Phase 2 Study Results in Hernia

SAN DIEGO, May 21, 2024 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "Cal...

2024-05-21 17:52 1074

Cali Biosciences Initiates Second Phase III Study of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use and Presents Consistent and Predictable PK Results Across Multiple Surgeries

* Subjects in Bunionectomy Study Dosed  * Data Presented at American Society for Pharmacology an...

2023-06-06 00:00 2704

Cali Biosciences Initiates Phase III Studies of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use

- Subjects in Herniorrhaphy Study Dosed - Successful FDA Interactions on Two Pre-clinical Pipeline P...

2023-04-19 11:05 1605

Cali Biosciences Announces Publications of Phase IIa Results of Long-Acting Ropivacaine (CPL-01)

CPL-01, for Non-Opioid Treatment of Post-Operative Pain, Garners Publication of Clinical Data in Ab...

2022-10-27 10:07 1932

Cali Biosciences Announces Successful Results in Phase IIb Study of Long-Acting Ropivacaine (CPL-01) for Non-Opioid Treatment of Post-Operative Pain

SAN DIEGO, March 21, 2022 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "C...

2022-03-22 00:00 1753

ASRA 2021 | Cali Biosciences Presents Phase IIa Clinical Data on CPL-01, a Long-Acting Ropivacaine

SAN DIEGO, Nov. 19, 2021 /PRNewswire/ -- Cali Biosciences, a global biopharmaceutical company focus...

2021-11-19 13:14 1236

Cali Biosciences Initiates Phase 2b Study of Long-Acting Ropivacaine for Non-Opioid Treatment of Post-Operative Pain

SAN DIEGO, Aug. 11, 2021 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "Ca...

2021-08-12 10:28 1263